Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
Clinical trial NCT04819841 · RECRUITING
Trial details
- NCT number
- NCT04819841
- Sponsor
- Kamau Therapeutics
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-15
- Primary completion
- 2026-12-31
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.